2010
Persistence of Cardiovascular Risk After Rofecoxib Discontinuation
Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persistence of Cardiovascular Risk After Rofecoxib Discontinuation. JAMA Internal Medicine 2010, 170: 2035-2036. PMID: 21149763, PMCID: PMC3024905, DOI: 10.1001/archinternmed.2010.461.Peer-Reviewed Original Research
2009
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose
2008
The ADVANTAGE seeding trial: a review of internal documents.
Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals Of Internal Medicine 2008, 149: 251-8. PMID: 18711155, DOI: 10.7326/0003-4819-149-4-200808190-00006.Peer-Reviewed Original ResearchGuest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 2008, 299: 1800-1812. PMID: 18413874, DOI: 10.1001/jama.299.15.1800.Peer-Reviewed Original Research
2007
What have we learnt from Vioxx?
Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? The BMJ 2007, 334: 120. PMID: 17235089, PMCID: PMC1779871, DOI: 10.1136/bmj.39024.487720.68.Commentaries, Editorials and Letters